Brief: Galera Reports Third Quarter 2022 Financial Results

Obsidian Therapeutics

09/11/2022 12:24

Nov 9 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND
RECENT
CORPORATE UPDATES
    * GALERA THERAPEUTICS INC Q3 LOSS PER SHARE $0.60
    * ON TRACK TO SUBMIT NDA TO U.S. FDA FOR AVASOPASEM BY END
OF 2022
    * AS OF SEPTEMBER 30, 2022, CO HAD CASH, CASH EQUIVALENTS
AND
SHORT-TERM INVESTMENTS OF $42.8 MILLION
    * CO EXPECTS EXISTING CASH, CASH EQUIVALENTS & SHORT-TERM
INVESTMENTS WILL ENABLE CO TO FUND OPERATING EXPENSES & CAPEX
REQUIREMENTS INTO H2 OF 2023

Source text for Eikon:  ID:nGNX6j9Nxk 
Further company coverage:  GRTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))